Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Gross Margin (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Gross Margin for 3 consecutive years, with 86.72% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 42.0% to 86.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 87.09% through Dec 2025, up 152.0% year-over-year, with the annual reading at 87.09% for FY2025, 152.0% up from the prior year.
  • Gross Margin for Q4 2025 was 86.72% at Phathom Pharmaceuticals, down from 87.5% in the prior quarter.
  • The five-year high for Gross Margin was 87.5% in Q3 2025, with the low at 75.51% in Q4 2023.
  • Average Gross Margin over 3 years is 83.95%, with a median of 86.72% recorded in 2025.
  • The sharpest move saw Gross Margin surged 1163bps in 2024, then plummeted -42bps in 2025.
  • Over 3 years, Gross Margin stood at 75.51% in 2023, then increased by 15bps to 87.14% in 2024, then dropped by 0bps to 86.72% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 86.72%, 87.5%, and 87.25% for Q4 2025, Q3 2025, and Q2 2025 respectively.